Interestingly, in contrast to our initial assumption and based on previous studies analyzing several EV membrane markers, such as endothelial injury markers (CD144, CD62E, CD34+41) and VEGFR1/2, white blood cells markers (CD11+ and CD14+), or the coagulation proteins (TF and TFPI and EPCR), we found no distinct pattern between patients pre- and post-chemotherapy in any of the cancer patients. The gene discussed is FLT1; the disease is cancer.